Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Custom Model Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Preclinical Solutions
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Drug Classification
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login

Custom Rodent Gene Editing Models

From gene disruption to precise knockin, humanization, reporter insertion, and transgenic expression, Cyagen delivers custom genetically engineered rodent models designed for reliable disease modeling, gene function studies, and preclinical research.

One Integrated Platform for Rodent Genome Engineering

{{ item.title }}
{{static_tabs[0].title}}

Translate Your Research Question

Rodent gene editing is not a one-size-fits-all process. Different research goals require different engineering strategies, from deleting a critical exon to inserting a human disease mutation, replacing a rodent gene with its human counterpart, or introducing a transgene for controlled expression studies.

Rodent gene editing is not a one-size-fits-all process. Different research goals require different engineering strategies, from deleting a critical exon to inserting a human disease mutation, replacing a rodent gene with its human counterpart, or introducing a transgene for controlled expression studies.

Instead of separating projects by technology name, Cyagen focuses on the biological outcome you need. Our team helps translate your research question into the right model design.

Research Objective Recommended Animal Model Schematic diagram
Investigating fundamental gene functions, exploring disease mechanisms, or validating new therapeutic targets. Conventional Knockout Model
Circumventing embryonic lethality, exploring tissue-specific biology, or triggering inducible disease states. Conditional Knockout Model
Replicating patient-specific genetic alterations, rare variants, or targeted disease-associated point mutations. Point Mutation/Precise Knockin Model
Assessing translational pharmacology, testing biologics, or studying targets unique to human biology. Humanized Model
Monitoring cellular lineages, mapping pathway activation, or observing gene expression dynamics. Reporter Knockin Model
Replicating intricate multi-domain gene structures, extensive human genetic loci, or broad regulatory sequences. Large-Fragment Knockin or BAC-Based Model
Investigating the effects of gene overexpression, assessing enhancer functions, or modeling transgene-driven phenotypes. Transgenic Model
Ensuring robust and stable transgene expression during preclinical model development. PiggyBac Transgenic Model
Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.

Why Choose Cyagen for Rodent Gene Editing?

Our team helps match your research objective to the right model type, whether the best approach is knockout, conditional knockout, knockin, humanization, reporter insertion, or transgenic expression.
Cyagen combines targeted gene editing, ES cell-based strategies, TurboKnockout™ technology, and transgenic model generation to support diverse project requirements.
From point mutations and safe harbor knockins to conditional alleles and large-fragment insertions, we support complex rodent genome engineering projects.
Standard services are commonly performed in C57BL/6, with additional strain options available depending on the project design.
Projects can include genotyping, sequencing, founder screening, breeding, germline transmission confirmation, and delivery of study-ready animals.
Cyagen can support the full process from strategy design to final cohort delivery, helping reduce technical burden and accelerate research timelines.
{{static_tabs[1].title}}

Workflow and Delivery

Cyagen provides end-to-end rodent gene editing support, with flexible entry points depending on your project stage. We can manage the full workflow or support selected phases such as vector construction, embryo injection, founder screening, breeding, validation, and cohort delivery.
Notes
  • Turnaround times: Estimated turnaround times exclude periods required for host institution approval, rodent importation approval, shipping, or transit.
  • Pricing and custom requests: Pricing details are available upon inquiry. For specific strain requests, larger knockin fragments, extended breeding, or other custom requirements, please contact us for detailed information and pricing.
  • Strain information: Standard services are primarily performed in the C57BL/6 or SD strain. Other strains may be available upon request.
  • Knockin fragment size: Standard knockin services support fragment insertion of up to 8 kb. Larger fragments may require additional time, cost, and customized project evaluation.
  • Embryo-based transgenic options: Transgenic rodent embryos, including PiggyBac transgenic rodent embryos where applicable, are available for projects focused on early developmental or embryonic gene function studies, such as enhancer analysis. This provides a streamlined option for studies that do not require maintaining a full rodent line.
->Start Your Project
{{static_tabs[2].title}}

Frequently Asked Questions (FAQs)

A rodent gene editing model is a genetically engineered rodent in which a specific gene or genomic sequence has been deleted, inserted, replaced, modified, or externally introduced. These models help researchers study gene function, disease mechanisms, therapeutic targets, and drug response in vivo.
Knockout models disrupt or remove gene function. Knockin models introduce a defined sequence change or insertion at a specific genomic locus. Transgenic models introduce exogenous genetic material to express a new trait or study gene regulation. In practice, these are different model outcomes within the broader field of rodent gene editing.
A conditional knockout model is recommended when complete gene deletion may cause embryonic lethality, systemic toxicity, or unclear phenotypes. Conditional strategies allow gene inactivation in selected tissues, cell types, or developmental stages.
Safe harbor loci such as ROSA26 or H11 are often used when researchers need stable transgene expression while minimizing disruption to endogenous gene function. This approach is suitable for reporter expression, human gene expression, and controlled model development.
Yes. Cyagen supports complex gene editing strategies, including large-fragment knockin and BAC-based transgenic approaches. The recommended method depends on the insert size, target locus, expression requirements, and downstream study goals.
C57BL/6 and SD are commonly used as a standard background, while other strain options may be available depending on the specific model design, technical route, and project requirements.
Useful starting information includes the target gene, desired modification, reference sequence, preferred strain, intended research application, expected deliverables, and whether you need founders, F1 animals, validated lines, or study-ready cohorts.
Yes. Cyagen can review your research objective and recommend the most suitable model strategy, including knockout, conditional knockout, knockin, humanized, reporter, regular transgenic, or PiggyBac transgenic approaches.
{{static_tabs[3].title}}

Publication

{{item.title}}
{{item.journal}} {{ item.date ? '(' + item.date + ')' : '' }} | {{item.products.title}}
Previous Page
Next Page

Overview of Genetically Engineered Animals

Knockout Mice
Mice with targeted gene deletions for gene function and disease studies.
Knockin Mice
Mice with specific genes inserted to study gene functions and disease.
Transgenic Mice
Mice with extra genes to study gene expression and its role in diseases.
Knockout Rats
Rats with gene knockouts to investigate gene function and disease models.
Knockin Rats
Rats with inserted genes for advanced functional studies and disease research.
Transgenic Rats
Rats with additional genes to explore gene expression and disease mechanisms.
Contact Us
Connect with our experts for your viral vector packaging needs. Please fill out the form below to start a conversation or request a quote.
Contact Information
Full Name
Email
Phone Number
+
-
 
Organization
Job Role
Country
Vector Type
AAV Packaging Functional Type
 
Is Tissue-Specific Targeting Required?
Gene Details
Gene Name
Fluorescent Protein/Luciferase
 
Promoter Requirements
Other Requirements
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research